L and lipid profiles in subjects with metabolic syndrome after supplementation

L and lipid profiles in subjects with metabolic syndrome after supplementation with water extracts of GP. In this study, we found that GP and its partially purified fraction could down-regulate PGC-1 expression, resulting in the inhibition of gluconeogenesis, lipogenesis, and HBV replication. These observations suggest that GP/HH-F3 is a potential agent to be used for the treatment of HBV-related fibrosis/cancer with metabolic syndrome. RESULTS Pathway analysis of up- and down-regulated genes in hepatocellular carcinoma Pathway analysis of our collected HCC gene signatures from EHCO3 indicates that up-regulated genes are mainly enriched in signaling, infection and cell cyclerelated pathways, whereas down-regulated genes are enriched in 181223-80-3 metabolism pathways related to lipid synthesis, glycolysis, and amino acid metabolism. The up-regulated genes are mostly factors modulating signaling pathways in tumor cells to maintain the production of necessary materials for proliferation, and many of them are drug targets such as mitogen-activated protein kinase. On the other hand, the down-regulated genes are mainly involved in lipid, amino acids, cytochrome P450, and glycolysis-related pathways. Down-regulation of enzymes might BIRB796 implicate that some metabolic reactions have been slowed down and resulted in the accumulation of upstream PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19861655 intermediates, such as glucose-6-phosphate and 3-phosphoglycerate, which could be used by pathways needed for HCC to proliferate. Recent studies also support that metabolic reprogramming is the core hallmark of cancer, and one of the functions of activated oncogenes and inactivated Oncotarget presented here to illustrate the pathways enriched by up- and down-regulated genes, respectively. Up-regulated genes were mainly enriched in signaling, infection, and cell cycle-related pathways, whereas down-regulated genes were enriched only in metabolism pathways related to lipid synthesis, glycolysis, amino acid metabolism, and P450 metabolism. Each node represents a pathway, and the number of genes in the pathway determines the size of the node. The larger the pathway, the bigger the size of the node is. The P-value from pathway enrichment analysis determines the redness of the balls. The lower the p-value, the redder the node is. The thickness of the lines between nodes in the network represents the number of genes that the two pathways have in common. The blueprint of metabolism pathways adapted from KEGG to illustrate dysregulated reactions based on EHCO3. Purple lines are reactions whose enzymes in HCC could be reversed from down-regulation to up-regulation by GP/HH-F3, whereas blue lines are reactions whose enzyme expression levels could be suppressed by GP/HH-F3. Huh7 cells were treated with 30% DMSO GP extracts and HH-F3 for 24 h, respectively. Western blot shows the effects after GP/HH-F3 treatment for HK2, PKM2, pyruvate dehydrogenase complex, phosphorylated PDH and PDHK with GAPDH used as a control. GP/HH-F3 could influence the TCA cycle via down-regulation of phosphorylated PDH, but GP/HH-F3 could not affect other molecules in the TCA cycle. A possible mechanism describing how GP/HH-F3 restores dysregulated glycolysis. Glucose-6phosphate, 3-phosphoglycerate, and phosphoenolpyruvate are key intermediates in glycolysis. www.impactjournals.com/oncotarget 7790 Oncotarget tumor suppressors is to reprogram cellular metabolism. Here, we employed the blueprint of metabolism pathways adapted from KEGG to illustrate dysregulat.L and lipid profiles in subjects with metabolic syndrome after supplementation with water extracts of GP. In this study, we found that GP and its partially purified fraction could down-regulate PGC-1 expression, resulting in the inhibition of gluconeogenesis, lipogenesis, and HBV replication. These observations suggest that GP/HH-F3 is a potential agent to be used for the treatment of HBV-related fibrosis/cancer with metabolic syndrome. RESULTS Pathway analysis of up- and down-regulated genes in hepatocellular carcinoma Pathway analysis of our collected HCC gene signatures from EHCO3 indicates that up-regulated genes are mainly enriched in signaling, infection and cell cyclerelated pathways, whereas down-regulated genes are enriched in metabolism pathways related to lipid synthesis, glycolysis, and amino acid metabolism. The up-regulated genes are mostly factors modulating signaling pathways in tumor cells to maintain the production of necessary materials for proliferation, and many of them are drug targets such as mitogen-activated protein kinase. On the other hand, the down-regulated genes are mainly involved in lipid, amino acids, cytochrome P450, and glycolysis-related pathways. Down-regulation of enzymes might implicate that some metabolic reactions have been slowed down and resulted in the accumulation of upstream PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19861655 intermediates, such as glucose-6-phosphate and 3-phosphoglycerate, which could be used by pathways needed for HCC to proliferate. Recent studies also support that metabolic reprogramming is the core hallmark of cancer, and one of the functions of activated oncogenes and inactivated Oncotarget presented here to illustrate the pathways enriched by up- and down-regulated genes, respectively. Up-regulated genes were mainly enriched in signaling, infection, and cell cycle-related pathways, whereas down-regulated genes were enriched only in metabolism pathways related to lipid synthesis, glycolysis, amino acid metabolism, and P450 metabolism. Each node represents a pathway, and the number of genes in the pathway determines the size of the node. The larger the pathway, the bigger the size of the node is. The P-value from pathway enrichment analysis determines the redness of the balls. The lower the p-value, the redder the node is. The thickness of the lines between nodes in the network represents the number of genes that the two pathways have in common. The blueprint of metabolism pathways adapted from KEGG to illustrate dysregulated reactions based on EHCO3. Purple lines are reactions whose enzymes in HCC could be reversed from down-regulation to up-regulation by GP/HH-F3, whereas blue lines are reactions whose enzyme expression levels could be suppressed by GP/HH-F3. Huh7 cells were treated with 30% DMSO GP extracts and HH-F3 for 24 h, respectively. Western blot shows the effects after GP/HH-F3 treatment for HK2, PKM2, pyruvate dehydrogenase complex, phosphorylated PDH and PDHK with GAPDH used as a control. GP/HH-F3 could influence the TCA cycle via down-regulation of phosphorylated PDH, but GP/HH-F3 could not affect other molecules in the TCA cycle. A possible mechanism describing how GP/HH-F3 restores dysregulated glycolysis. Glucose-6phosphate, 3-phosphoglycerate, and phosphoenolpyruvate are key intermediates in glycolysis. www.impactjournals.com/oncotarget 7790 Oncotarget tumor suppressors is to reprogram cellular metabolism. Here, we employed the blueprint of metabolism pathways adapted from KEGG to illustrate dysregulat.